By Steven Scheer and Tova Cohen TEL AVIV (Reuters) – Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan. …
Source:Teva shares slide on generic Copaxone fears
Sunday, April 19, 2015
Teva shares slide on generic Copaxone fears
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment